Business
Aeolus Announces Fiscal Year 2015 Financial Results
Aeolus Announces Fiscal Year 2015 Financial Results.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":"\nAeolus Announces Fiscal Year 2015 Financial Results \n\nAeolus Announces Fiscal Year 2015 Financial Results\n\n\n MISSION VIEJO, CA--(Marketwired - December 18, 2015) - \n Aeolus Pharmaceuticals, Inc.\n (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced today financial results for the three months and twelve months ended September 30, 2015.\n Key Fiscal Year 2015 Operational Accomplishments\n \n Reported strong secondary endpoint data from our Non-Human Primate (\"NHP\") efficacy study in pulmonary Acute Radiation Syndrome (\"Lung-ARS\") supporting the significant improvement in survival reported after treatment with AEOL 10150 in NHP's exposed to lung irradiation: In addition to doubling survival at 180 days after exposure, treatment with AEOL 10150: Increased mean and median overall survival time and mean and median survival in subjects that did not survive to 180 daysIncreased time to onset of increased respiratory rate, a clinical measure of lung injuryDecreased mortality in subjects with elevated respiratory rateDecreased wet lung weight in all animals, suggesting less parenchymal damage and edemaIncreased Sp02, a measure of compensated lung functionDiminished radiographic evidence of pneumonitis and fibrosis during the later stages of the study (days 90-180)\n Received notice from the Office of Orphan Products Development at the U.S. Food & Drug Administration (FDA) granting Orphan Drug Designation for AEOL 10150 \"for treatment of idiopathic pulmonary fibrosis.\"\n Announced the formation of a Clinical Advisory Board for Idiopathic Pulmonary Fibrosis chaired by Dr. Kevin Brown of National Jewish Health.\n Filed a provisional patent application with the United States Patent Office for a new series of compounds, licensed from National Jewish Health, demonstrating anti-microbial and anti-inflammatory action.\n Received a Notice of Allowance from the Israeli Patent Office for AEOL 10150 for treating injury associated with exposure to alkylating agents such as sulfur mustard gas\n Received a Notice of Allowance of a composition of matter patent from the European Patent Office for its oral Parkinson's disease drug, AEOL 11114 following development in collaboration with the Michael J. Fox Foundation for ...